Whitehawk Therapeutics is progressing three antibody drug conjugate (ADC) cancer therapies, with Phase 1 trials ongoing for HWK-007 and HWK-016 and a new Phase 1 trial started for HWK-206, which has FDA Fast Track status. Initial Phase 1 data for HWK-007 and HWK-016 is expected in the first half of 2027, and for HWK-206 by the end of 2027. The company reported $169.7 million in cash and investments as of September 30, 2026, sufficient to fund operations into the second half of 2028. These developments highlight Whitehawk's focus on treating difficult cancers like small-cell lung cancer and ovarian cancer with advanced ADC technology.
Whitehawk Therapeutics' recent financial and clinical updates provide context for readers interested in biopharma developments. For readers following the health sector, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: Among 150 priced US health stocks, 121 rose and 18 fell today. Inovio Pharmaceuticals Inc (INO) gained 8.64% to USD 1.32 with a typical hold time of 41 days, contrasting with LifeStance Health Group Inc. (LFST), which dropped 5.66% to USD 12.99 and has a shorter typical hold time of 12 days. Cassava Sciences Inc (FLNA) also rose 5.94% to USD 0.48, holding for about 39 days on average.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
